New drug combo aims to keep relapsed myeloma in check after second transplant
NCT ID NCT03030261
First seen Jan 12, 2026 · Last updated May 24, 2026 · Updated 22 times
Summary
This study tests whether a combination of three drugs (elotuzumab, pomalidomide, and dexamethasone) given after a second stem cell transplant can help people with multiple myeloma that has come back. The goal is to keep the cancer under control for as long as possible. The study involves 25 participants whose myeloma relapsed after their first transplant and one or two prior treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA IN RELAPSE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Colorado Blood Cancer Institute (Sarah Cannon)
Denver, Colorado, 80218, United States
-
University Health Network - Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.